Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
WASHINGTON — Federal regulators ordered Pfizer Inc. to stop running a print advertisement for cholesterol-lowering drug Lipitor, saying the ad’s claim that Lipitor can cut the risk of heart disease is misleading.
The Food and Drug Administration told Pfizer (PFE) that an eight-page ad for Lipitor that recently ran in a medical journal creates “an overwhelming impression” that Lipitor can reduce the risk of developing coronary heart disease.
Although Lipitor can be promoted as a cholesterol-lowering drug, it hasn’t received FDA approval as a treatment for coronary heart disease.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in